skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

15319

Galectin-3: clinical utility and prognostic value in patients with heart failure



Review

(3882) Total Article Views


Authors: Kramer F

Published Date February 2013 Volume 2013:4 Pages 13 - 22
DOI: http://dx.doi.org/10.2147/RRCC.S28562

Frank Kramer

Clinical Sciences, Global Biomarker Strategy and Development, Bayer HealthCare, Wuppertal, Germany

Abstract: This review summarizes the key findings of 14 clinical trials in which Galectin-3 was assessed as a biomarker of heart failure. In addition, most relevant information available about Galectin-3 biology generated in in vitro and in vivo research is discussed in the context of heart failure.

Keywords: biomarker, cardiovascular disease, therapy monitoring, prediction of outcome, patient stratification



Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read: